drugset / Trial / NCT01580839

EXTEND (International): Extending the Time for Thrombolysis in Emergency Neurological Deficits (International)

NCT01580839

RandomizedParallel-groupTriple-blindTreatment

Summary

The primary hypothesis being tested in this trial is that ischaemic stroke patients selected with significant penumbral mismatch (according to imaging criteria) at 4.5 (or 3 hours depending on local guidelines) - 9 hours post onset of stroke or after 'wake up stroke' (WUS) will have improved clinical outcomes when given intravenous tissue plasminogen activator (tPA) compared to placebo.

Timeline

Start
2012-12-06
Primary completion
2018-08-22
Completion
2018-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 0.9 mg/kg Intravenous

Indications